<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oral inotropes did not always improve mortality of the patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> partly because of possible direct toxic effects of these agents on myocytes, exacerbating <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, enhancing neurohormonal activity </plain></SENT>
<SENT sid="1" pm="."><plain>Ca(2 +) sensitizers such as <z:chebi fb="0" ids="32003">pimobendan</z:chebi> and <z:chebi fb="0" ids="50567">levosimendan</z:chebi> was expected to improve even mortality of the patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> through increasing cardiac contractility without a rise in intracellular calcium </plain></SENT>
<SENT sid="2" pm="."><plain>However, the trials using these agents disappoint our expectations </plain></SENT>
<SENT sid="3" pm="."><plain>We need the development of the agents which has more specific effect of Ca(2 +) sensitizing and the selection of the patients who will receive the benefits of Ca(2 +) sensitizers </plain></SENT>
</text></document>